[1] |
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update[J]. Allergy, 2014, 69(7): 868⁃887. DOI: 10.1111/all.12313.<br />
|
[2] |
Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema[J]. Clin Exp Allergy, 2015, 45(3): 547⁃565. DOI: 10.1111/cea.12494.<br />
|
[3] |
中华医学会皮肤性病学分会免疫学组. 中国荨麻疹诊疗指南(2014版)[J]. 中华皮肤科杂志, 2014, 47(7): 514⁃516. DOI:10.3760/cma.j.issn.0412⁃4030.2014.07.019.<br />
|
[4] |
Breneman D, Bronsky EA, Bruce S, et al. Cetirizine and astemi⁃zole therapy for chronic idiopathic urticaria: a double⁃blind, placebo⁃controlled, comparative trial[J]. J Am Acad Dermatol, 1995, 33(2 Pt 1): 192⁃198. DOI: 10.1016/0190⁃9622(95)90233⁃3.<br />
|
[5] |
郝飞, 李惠, 鲁元刚, 等. 左西替利嗪与西替利嗪治疗慢性荨麻疹多中心随机双盲对照研究[J]. 中华皮肤科杂志, 2004, 37(6): 320⁃322.<br />
|
[6] |
Holness DL. Results of a quality of life questionnaire in a patch test clinic population[J]. Contact Dermatitis, 2001, 44(2): 80⁃84. DOI: 10.1034/j.1600⁃0536.2001.440204.x.<br />
|
[7] |
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)⁃⁃a simple practical measure for routine clinical use[J]. Clin Exp Dermatol, 1994, 19(3): 210⁃216. DOI: 10.1111/j.1365⁃2230.1994. tb01167.x.<br />
|
[8] |
郝飞, 钟华. 慢性荨麻疹发病机制和治疗策略的思考[J]. 中华皮肤科杂志, 2010, 43(1): 2⁃5. DOI: 10.3760/cma.j.issn.0412⁃4030.2010.01.002.<br />
|
[9] |
董丹, 陈艳明, 郭田章, 等. 玉屏风颗粒联合非索非那定治疗慢性荨麻疹的临床疗效及对患者生活质量的影响[J]. 中国皮肤性病学杂志, 2015(9): 987⁃989. DOI: 10.13735/j.cjdv.1001⁃7089.201501117.<br />
|
[10] |
许璇璇, 李玲孺, 武彦伶, 等. 从表虚伏邪探讨玉屏风散双向免疫调节机制[J]. 安徽中医药大学学报, 2015, 34(2): 1⁃3. DOI: 10.3969/j.issn.2095⁃7246.2015.02.001.<br />
|
[11] |
Jie Q, Kodithuwakku ND, Yuan X, et al. Anti⁃allergic and anti⁃inflammatory properties of a potent histamine H1 receptor antagonist, desloratadine citrate disodium injection, and its anti⁃inflammatory mechanism on EA.hy926 endothelial cells[J]. Eur J Pharmacol, 2015, 754: 1⁃10. DOI: 10.1016/j.ejphar.2015.02.016.<br />
|